Willow LegitScript and Accreditation Status: Is Willow Legit?

What Is Willow and What Services Does It Offer?

Willow is a cash-pay telehealth platform that markets GLP-1 weight-loss programs and women's hormonal health services, including hormone replacement therapy and fertility-adjacent support. It operates without accepting traditional insurance, positioning itself in the growing direct-to-consumer telehealth segment that saw roughly 116 million telehealth visits in the United States in 2023, according to the CDC's National Center for Health Statistics [1].

The Cash-Pay Telehealth Model

Cash-pay platforms remove the insurance prior-authorization step, which can reduce wait times. The tradeoff is that patients bear full cost and lose the pharmacy-benefit safeguard that typically routes prescriptions through NABP-accredited dispensers.

The FDA regulates GLP-1 receptor agonists as prescription drugs. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) each carry full FDA approval for specific indications, and the agency maintains a current list of approved GLP-1 products [2]. Any compounded version of these molecules exists outside standard FDA approval pathways, which carries meaningful risk that the FDA has documented explicitly [3].

Who Runs the Clinical Team?

Willow markets board-certified clinicians but does not publish individual prescriber NPI numbers on its public-facing marketing pages. Patients should request the full NPI of any treating clinician and verify active licensure through the NPPES NPI Registry [4] and through their specific state medical board before consenting to treatment.

LegitScript Certification: What It Is and Why It Matters

LegitScript is an independent certification and monitoring company whose standards are used by Google, Microsoft, and major payment processors to decide whether an online pharmacy or telehealth platform may advertise on their networks. A company certified by LegitScript has agreed to regular compliance audits, verified prescriber credentials, and pharmacy legitimacy reviews.

How to Check LegitScript Status Yourself

The LegitScript verification database is publicly searchable at no cost [5]. Entering a website URL returns one of four statuses: Certified, Not Recommended, Rogue, or Illegitimate. As of the publication date of this article, Willow does not appear in the Certified category of that database.

Absence from the Certified list does not automatically mean a platform is unsafe. Certification is voluntary. Several legitimate hospital systems and specialty clinics have never applied. The absence does mean, however, that no independent third party has audited the platform's prescribing workflows, pharmacy partners, or clinician credentials.

What LegitScript Audits Actually Check

LegitScript's telehealth certification standard requires platforms to confirm that:

• Every prescriber holds a valid, active, unrestricted license in the patient's state.
• Prescriptions are issued only after a legitimate patient-provider relationship is established.
• Dispensing pharmacies are licensed in the states to which they ship.
• The platform does not dispense controlled substances without meeting DEA requirements.

The full criteria are published in LegitScript's telehealth program standards [6]. Willow has not, as of this review, submitted to this audit process.

FDA Compliance and the Compounded GLP-1 Question

The FDA placed semaglutide on its drug shortage list [7] beginning in 2022, which temporarily allowed 503A and 503B pharmacies to compound semaglutide legally. The FDA announced resolution of the semaglutide shortage in March 2025 and tirzepatide shortage resolution in late 2024, which changes the legal status of compounded versions significantly.

The Shortage Resolution and Its Consequences

After shortage resolution, 503A pharmacies may no longer compound copies of commercially available brand-name GLP-1 drugs as a standard practice. The FDA's guidance on 503A pharmacy compounding [8] makes clear that routine compounding of a drug that is neither on the shortage list nor on the 503A bulk drug substances list is not permitted.

Platforms that continued marketing compounded semaglutide or tirzepatide after shortage resolution were subject to FDA enforcement action. The agency issued warning letters to several telehealth entities [9] in 2024 and 2025 for exactly this practice.

What This Means for Willow Patients

If Willow is prescribing compounded semaglutide or tirzepatide after the FDA's declared shortage resolution, patients may be receiving a drug product that falls outside the current legal compounding framework. Patients should ask their Willow clinician directly whether the prescribed product is:

1. An FDA-approved brand-name GLP-1 (Wegovy, Ozempic, Zepbound, Mounjaro).
2. A compounded version from a 503B outsourcing facility currently authorized to compound it.
3. A compounded version from a 503A pharmacy, with documentation of a patient-specific need.

The FDA's BeSafeRx consumer safety page [10] outlines what patients should verify before accepting any prescription drug from an online platform.

NABP and Pharmacy Accreditation

The National Association of Boards of Pharmacy operates the VIPPS (Verified Internet Pharmacy Practice Sites) accreditation program [11], which independently confirms that an online pharmacy is licensed, operates legally, and meets patient safety standards. Any dispensing pharmacy used by Willow should appear in the NABP VIPPS database.

How to Verify the Dispensing Pharmacy

A patient receiving a prescription through Willow should:

1. Ask for the dispensing pharmacy's full legal name, state of licensure, and NPI or NABP e-Profile number.
2. Search that pharmacy in the NABP pharmacy database [12].
3. Confirm the pharmacy holds an active license in the patient's state of residence, since interstate pharmacy shipping requires both origin and destination state licensing.

A pharmacy that is not in the NABP database is not automatically illegal, but the absence of VIPPS accreditation removes an important patient-safety checkpoint.

BBB Rating and Patient Complaints

The Better Business Bureau assigns ratings based on complaint volume, complaint resolution, business transparency, and time in operation. Willow's BBB profile should be verified directly at bbb.org [13] because ratings change frequently as new complaints are filed or resolved.

Common Complaint Patterns in GLP-1 Telehealth

Across the broader GLP-1 telehealth category, the most common BBB and CFPB complaint types involve:

• Difficulty canceling subscriptions after the first shipment.
• Billing for medication that was delayed, backordered, or never shipped.
• Failure to provide refunds after FDA compounding status changes forced supply disruptions.
• Clinical staff unresponsive after adverse effects were reported.

These patterns are not unique to Willow. The FTC has published consumer guidance [14] on subscription traps in health and wellness services. Patients considering Willow should read the cancellation and refund policy in full before entering payment information.

How to File a Complaint

If a patient experiences a prescribing, billing, or medication-safety issue with any telehealth platform, the appropriate reporting channels are:

• The state medical board where the prescriber is licensed (for clinical concerns).
• The FDA MedWatch program at fda.gov/medwatch [15] for adverse drug events.
• The FTC at reportfraud.ftc.gov for billing fraud.
• The BBB at bbb.org for business-practice disputes.

Clinical Efficacy of GLP-1 Therapy: Separating the Drug From the Platform

The underlying medications that platforms like Willow prescribe carry strong clinical evidence. The platform's regulatory status is a separate question from whether GLP-1 drugs work.

Key Trial Data

In the STEP-1 trial (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks compared with 2.4% in the placebo group (P<0.001) [16]. The SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide 15 mg produced mean weight loss of 22.5% at 72 weeks versus 2.4% placebo (P<0.001) [17].

These outcomes were achieved with FDA-approved doses of brand-name drugs administered under controlled trial conditions, not with compounded analogs.

Guideline Recommendations

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "We recommend using FDA-approved anti-obesity medications as adjuncts to lifestyle intervention in adults with obesity (BMI >30 kg/m2) or overweight (BMI 27.0 to 29.9 kg/m2) with at least one weight-related comorbidity" [18]. The guideline does not endorse compounded GLP-1 formulations as equivalent alternatives.

The American Diabetes Association's 2024 Standards of Care similarly specifies approved GLP-1 receptor agonists by brand name and dose and does not recognize compounded versions as interchangeable [19].

How to Evaluate Any GLP-1 Telehealth Platform, Including Willow

The framework below is specific to GLP-1 and women's health telehealth platforms. Use it before enrolling anywhere.

Step 1: Verify the Prescriber

Search the prescriber's full name and NPI at npiregistry.cms.hhs.gov [4]. Confirm the license is active and unrestricted in your state. If the platform will not provide an NPI, do not proceed.

Step 2: Check the Dispensing Pharmacy

Ask for the pharmacy's name and NABP e-Profile number. Search it at nabp.pharmacy [12]. A VIPPS-accredited pharmacy has passed independent safety and licensing review.

Step 3: Confirm the Drug Product

Ask whether your prescription is for an FDA-approved brand or a compounded formulation. If it is compounded, ask which 503A or 503B facility will prepare it and confirm that facility appears on the FDA's list of registered outsourcing facilities [20].

Step 4: Read the Cancellation Policy Before Paying

Confirm in writing (email or in-app message) the cancellation procedure, refund eligibility window, and what happens to pre-paid balances if the drug is discontinued or out of stock.

Step 5: Search LegitScript and BBB

Run the platform URL through legitscript.com/lookup [5] and read the current BBB profile at bbb.org [13]. Neither database is definitive, but both add signal.

State Medical Board Oversight of Telehealth Prescribing

Telehealth prescribing is governed by the laws of the state where the patient is located, not where the company is incorporated. Most states require the prescriber to hold an active, unrestricted license in the patient's state before issuing a prescription. The Federation of State Medical Boards maintains a policy on telehealth prescribing standards that most state boards have adopted [21].

The Ryan Haight Act

The Ryan Haight Online Pharmacy Consumer Protection Act prohibits internet prescribing of controlled substances without at least one in-person medical evaluation, with narrow DEA-approved exceptions. Though most GLP-1 drugs are not Schedule II-V controlled substances, any platform also offering testosterone, certain sleep aids, or stimulants must comply. The DEA's telemedicine prescribing regulations [22] apply regardless of how a platform markets itself.

Patients who receive prescriptions for controlled substances from any telehealth platform without an in-person evaluation should report the prescriber to their state medical board.

Women's Health-Specific Considerations

Willow markets specifically to women, emphasizing GLP-1 therapy alongside hormonal health. Women using GLP-1 agents have specific considerations that a responsible telehealth platform should address.

GLP-1 and Hormonal Contraception

Oral contraceptive efficacy may be reduced in women experiencing significant GI slowing from GLP-1 drugs, because absorption of the contraceptive pill depends on gastric transit time. The FDA's prescribing information for semaglutide notes this interaction explicitly [2]. Women using oral contraceptives alongside GLP-1 therapy should discuss backup contraception with their clinician.

GLP-1 Use in Pregnancy

The FDA classifies semaglutide as Pregnancy Category risk based on animal data showing fetal harm at doses below human exposure levels. The FDA prescribing label for Wegovy [23] recommends discontinuing semaglutide at least two months before planned conception. A platform serving reproductive-age women should screen for pregnancy intent before initiating GLP-1 therapy.

Hormone Therapy Prescribing Standards

The Menopause Society (formerly NAMS) publishes prescribing standards for hormone therapy at menopause.org [24]. Any telehealth platform offering HRT should align its clinical protocols with those evidence-based guidelines, including appropriate baseline labs and contraindication screening.